Affiliations 

  • 1 Department of Pathology, Qiqihar Hospital Affiliated to Southern Medical University, Qiqihar, China
  • 2 Department of Network Information, Fuling Central Hospital of Chongqing city, Chongqing, China
  • 3 Biorepository Department, Biomedical Research Administration, King Fahad Medical City, Riyadh, Saudi Arabia
  • 4 UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  • 5 Department of Pathology, Fuling Central Hospital of Chongqing city, Chongqing, China
Int J Clin Pract, 2021 Nov;75(11):e14764.
PMID: 34469629 DOI: 10.1111/ijcp.14764

Abstract

PURPOSE: Many studies have investigated the association between serum IGF-1 and IGFBP levels with gastric cancer (GC), but the results remained inconclusive. In this work, we performed a systematic review and meta-analysis to examine the precise association of serum levels of IGF-1 and IGFBP with GC.

METHODS: A comprehensive systematic search was carried out in PubMed/MEDLINE, SCOPUS, Web of Science, and EMBASE databases for (nested) case-control studies that reported the levels of IGF-1 and IGFBP in GC cases and healthy controls, from inception until October 2020. Weighted mean difference (WMD) was calculated for estimating combined effect size. Subgroup analysis was performed to identify the source of heterogeneity among studies.

RESULTS: We found eight and five eligible studies (with 1541 participants) which provided data for IGF-1 and IGFBP, respectively. All studies on IGFBP reported the IGFBP-3 isoform. The pooled results indicate that GC patients had significantly lower serum IGF-1 [WMD = -26.21 ng/mL (95% CI, -45.58 to -6.85; P = .008)] and IGFBP-3 [WMD = -0.41 ng/mL (95% CI, -0.80 to -0.01; P = .04; I2  = 89.9%; P 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.